-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Khkei8K2ZuaNzpAGZ5aCOTwl6SwFWxuChgBRYnFK2oRKKxXQtpdnYU2lKv7/H9EO aIGwVUWtPM5xbUhXg4d+8g== 0000708818-00-000002.txt : 20000214 0000708818-00-000002.hdr.sgml : 20000214 ACCESSION NUMBER: 0000708818-00-000002 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19991231 FILED AS OF DATE: 20000211 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QUALITY SYSTEMS INC CENTRAL INDEX KEY: 0000708818 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN [7373] IRS NUMBER: 952888568 STATE OF INCORPORATION: CA FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: SEC FILE NUMBER: 001-12537 FILM NUMBER: 532609 BUSINESS ADDRESS: STREET 1: 17822 E 17TH ST STE 210 CITY: TUSTIN STATE: CA ZIP: 92780 BUSINESS PHONE: 7147317171 MAIL ADDRESS: STREET 1: 178222 E 17TH STREET STREET 2: SUITE 210 CITY: TUSTIN STATE: CA ZIP: 92780 10-Q 1 1 U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE [X] SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 1999 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE [ ] SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-13801 QUALITY SYSTEMS, INC. (Exact name of registrant as specified in its charter) California 95-2888568 - ------------------------------- ------------------- (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 17822 East 17th Street, Suite 210 Tustin, California 92780 (Address of principal executive offices) (Zip Code) Issuer's telephone number, including area code: (714) 731-7171 NOT APPLICABLE (Former name, former address and former fiscal year, if changed, since last year) Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days. Yes XX No ---- ---- APPLICABLE ONLY TO CORPORATE ISSUERS: Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date. 6,197,891 shares of Common Stock, $.01 par value, as of January 28, 2000 2 PART I. CONSOLIDATED FINANCIAL INFORMATION. ------- ----------------------------------- Item 1. Financial Statements. - ------- --------------------- QUALITY SYSTEMS, INC. CONSOLIDATED BALANCE SHEETS (in thousands)
ASSETS December 31, March 31, 1999 1999 ------------- ------------- (Unaudited) Current Assets: Cash and cash equivalents $ 16,180 $ 14,196 Short-term investments 235 245 Accounts receivable, net 12,590 12,488 Inventories 1,141 772 Other current assets 1,049 1,019 ------------- ------------- Total current assets 31,195 28,720 Equipment and Improvements, net 1,646 1,783 Capitalized Software Costs, net 1,962 2,144 Deferred Tax Asset 3,081 3,254 Excess of Cost Over Net Assets of Acquired Business, net 2,197 2,452 Other Assets 1,721 1,865 ------------- ------------- Total assets $ 41,802 $ 40,218 ============= ============= LIABILITIES AND SHAREHOLDERS' EQUITY Current Liabilities: Accounts payable $ 1,124 $ 1,813 Deferred service revenue 5,130 4,484 Other current liabilities 3,980 4,257 ------------- ------------- Total liabilities 10,234 10,554 ------------- ------------- Commitments and Contingencies Shareholders' Equity: Common stock, $0.01 par value, 20,000 shares authorized, 6,206 and 6,214 shares issued and outstanding, respectively 62 62 Additional paid-in capital 35,517 35,568 Accumulated deficit (4,011) (5,966) ------------- ------------- Total shareholders' equity 31,568 29,664 ------------- ------------- Total liabilities and shareholders' equity $ 41,802 $ 40,218 ============= =============
See notes to consolidated financial statements. 3 QUALITY SYSTEMS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) (in thousands, except per share amounts)
Three Months Ended Nine Months Ended ------------------ ------------------ December 31, December 31, 1999 1998 1999 1998 -------- -------- -------- -------- Net Revenues: Sales of computer systems, upgrades and supplies $ 4,435 $ 5,000 $ 15,184 $ 13,338 Maintenance and other services 4,373 3,827 12,435 10,645 -------- -------- -------- -------- 8,808 8,827 27,619 23,983 Cost of Products and Services 4,023 4,037 12,547 11,510 -------- -------- -------- -------- Gross Profit 4,785 4,790 15,072 12,473 Selling, General and Administrative Expenses 3,166 3,390 9,344 10,072 Research and Development Costs 962 842 2,819 2,630 -------- -------- -------- -------- Income (Loss) from Operations 657 558 2,909 (229) Investment Income 183 109 531 260 -------- -------- -------- -------- Income before Provision for Income Taxes 840 667 3,440 31 Provision for Income Taxes 365 298 1,485 202 -------- -------- -------- -------- Net Income (Loss) and Comprehensive Income (Loss) $ 475 $ 369 $ 1,955 $ (171) ======== ======== ======== ======== Net Income (Loss) per Share, basic & diluted $ 0.08 $ 0.06 $ 0.31 $ (0.03) ======== ======== ======== ========
See notes to consolidated financial statements. 4 QUALITY SYSTEMS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (in thousands)
Nine Months Ended December 31, ----------------------------- 1999 1998 ------------ ------------ Cash Flows from Operating Activities: Net income (loss) $ 1,955 $ (171) Adjustments to reconcile net income (loss) to net cash provided by operating activities: Depreciation and amortization 1,990 1,870 Loss on short-term investments 31 242 Deferred income taxes 173 (253) Changes in: Accounts receivable (102) (117) Inventories (369) 453 Other current assets (30) (139) Other assets (76) (101) Accounts payable (689) 39 Deferred service revenue 646 1,247 Income taxes payable and taxes related to equity accounts (769) (277) Other current liabilities 492 (540) ------------ ------------ Net Cash Provided by Operating Activities 3,252 2,253 ------------ ------------ Cash Flows from Investing Activities: Net additions to equipment and improvements (298) (368) Additions to capitalized software costs (852) (953) Purchase of net assets of MicroMed Healthcare Information Systems, Inc. - (3,840) Purchase of short-term investment (50) (75) Proceeds from sale of short-term investment 29 515 Change in other assets (46) 18 ------------ ------------ Net Cash Used in Investing Activities (1,217) (4,703) ------------ ------------ Cash Flows from Financing Activities: Purchases of Common Stock (57) (150) Proceeds from exercise of stock options 6 50 ------------ ------------ Net Cash Used in Financing Activities (51) (100) ------------ ------------ Net Increase (Decrease) in Cash and Cash Equivalents 1,984 (2,550) Cash and Cash Equivalents, beginning of period 14,196 16,107 ------------ ------------ Cash and Cash Equivalents, end of period $ 16,180 $ 13,557 ============ ============
See notes to consolidated financial statements. 5 QUALITY SYSTEMS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (continued) (Unaudited) (in thousands) Supplemental Information - During the nine months ended December 31, 1999 and 1998, the Company made income tax payments, net of refunds received, of $2,099 and $719, respectively.
Nine Months Ended December 31, ----------------------------- 1999 1998 ------------ ------------ Detail of businesses acquired in purchase transaction: Purchased In-Process Research and Development $ - $ - Fair Value of Assets Acquired - - Liabilities Assumed - - Common Stock Issued in the Acquisition - (1,836) Retirement of Acquisition Obligation - 5,676 ------------ ------------ Cash Paid for the Acquisition, net of cash acquired $ - $ 3,840 ============ ============
See notes to consolidated financial statements. 6 QUALITY SYSTEMS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 1 - BASIS OF PRESENTATION - ------ --------------------- The accompanying unaudited consolidated financial statements have been prepared in accordance with the requirements of Form 10-Q and, therefore, do not include all information and footnotes which would be presented were such financial statements prepared in accordance with generally accepted accounting principles, and should be read in conjunction with the audited financial statements presented in the Company's Annual Report for the fiscal year ended March 31, 1999. In the opinion of management, the accompanying financial statements reflect all adjustments which are necessary for a fair presentation of the results of operations for the interim periods presented. The results of operations for such interim periods are not necessarily indicative of results of operations to be expected for the full year. NOTE 2 - ACQUISITION OF MICROMED HEALTHCARE INFORMATION SYSTEMS, INC. - ------ ------------------------------------------------------------ On May 15, 1997, the Company acquired substantially all of the assets of MicroMed Healthcare Information Systems, Inc. ("MicroMed"), a developer and marketer of proprietary information systems utilizing a graphical user interface client-server platform for medical group practices. The purchase price consisted of an initial cash payment of $4.8 million paid at the closing of the transaction and an additional payment, based upon certain operating results of MicroMed for the twelve-month period ended March 31, 1998, of $5.7 million due no later than June 29, 1998. The additional payment, paid on June 29, 1998, consisted of $3.8 million in cash and 245,454 shares of the Company's Common Stock valued at $1.8 million, or $7.48 per share. The shares of Common Stock could not be sold or otherwise transferred in any manner until June 1999. NOTE 3 - STOCK REPURCHASE - ------ ---------------- In February 1997, the Company's Board of Directors authorized the repurchase on the open market of up to 10% of the shares of the Company's outstanding Common Stock at various times through February 1998, subject to compliance with applicable laws and regulations. On February 9, 1998, the Company's Board of Directors extended this authorization through February 9, 1999 and on February 9, 1999 further extended this authorization through February 28, 2000. The timing and amount of any repurchase is at the discretion of the Company's management. The Company's management could, in the exercise of its judgment, repurchase fewer shares than authorized. During the three and nine months ended December 31, 1999, the Company repurchased 9,400 shares at a cost of $57,000. Since the inception of the repurchase authorization through January 28, 2000, 109,900 shares have been repurchased at a cost of $630,000. 7 NOTE 4 - INCOME TAXES - ------ ------------ The provision for income taxes for the three and nine months ended December 31, 1999 and 1998 differ from the expected combined statutory rates primarily due to the impact of non-deductible amortization of certain intangible assets acquired in the May 1996 acquisition of Clinitec International, Inc. and the effect of varying state income tax rates. NOTE 5 - NET INCOME (LOSS) PER SHARE - ------ --------------------------- The following table reconciles the weighted average shares outstanding for basic and diluted net income (loss) per share for the periods indicated.
Three Months Ended Nine Months Ended December 31, December 31, ------------------ ------------------ 1999 1998 1999 1998 -------- -------- -------- -------- (in thousands except per share amounts) Net income (loss) $ 475 $ 369 $ 1,955 $ (171) -------- -------- -------- -------- Basic net income (loss) per share: Weighted average number of common shares outstanding 6,208 6,242 6,213 6,162 -------- -------- -------- -------- Basic net income (loss) per share $ 0.08 $ 0.06 $ 0.31 $ (0.03) ======== ======== ======== ======== Diluted net income (loss) per share: Weighted average number of common shares outstanding 6,208 6,242 6,213 6,162 Weighted average number of common shares equivalents- Weighted average options outstanding 10 1 10 - -------- -------- -------- -------- Weighted average number of common and common equivalent shares 6,218 6,243 6,223 6,162 -------- -------- -------- -------- Diluted net income (loss) per share $ 0.08 $ 0.06 $ 0.31 $ (0.03) ======== ======== ======== ========
The net loss per share, basic and diluted, for the nine months ended December 31, 1998 was computed using the weighted average number of shares actually outstanding during the period and any common share equivalents were excluded because their impact would have been anti- dilutive. 8 Item 2. Management's Discussion and Analysis of Financial Condition - ------- ----------------------------------------------------------- and Results of Operations. -------------------------- Except for the historical information contained herein, the matters discussed in this Quarterly Report on Form 10-Q, including discussions of the Company's product development plans and business strategies and market factors influencing the Company's results, are forward-looking statements that involve certain risks and uncertainties. Actual results may differ from those anticipated by the Company as a result of various factors, both foreseen and unforeseen, including, but not limited to, the Company's ability to continue to develop new products and increase systems sales in a market characterized by rapid technological evolution, consolidation, and competition from larger, better capitalized competitors. Many other economic, competitive, governmental and technological factors could impact the Company's ability to achieve its goals and interested persons are urged to review the risks described below, as well as in the Company's other public disclosures and filings with the Securities and Exchange Commission. COMPANY OVERVIEW. Quality Systems, Inc. ("QSI") and its wholly-owned subsidiaries, Clinitec International, Inc. ("Clinitec") and MicroMed Healthcare Information Systems, Inc. ("MicroMed"), (collectively, the "Company") develop and market healthcare information systems that automate medical and dental group practices, physician hospital organizations ("PHOs"), management service organizations ("MSOs"), community health centers and dental schools. In response to the growing need for more comprehensive, cost- effective information solutions for physician and dental practices, the Company's systems provide its clients with the ability to redesign patient care and other workflow processes, improve productivity, reduce information processing and administrative costs, and provide multi-site access to patient information. The Company's proprietary software systems include general patient information, electronic medical records, appointment scheduling, billing, insurance claims submission and processing, managed care plan implementation and referral management, treatment outcome studies, treatment planning, drug formularies, dental charting, and letter generation. In addition to providing fully integrated software information solutions to its clients, the Company offers comprehensive hardware and software installation services, maintenance and support services, system training services, and electronic insurance claims submission services. The Company currently has an installed base of more than 600 healthcare information systems serving PHOs, MSOs, group practices, specialty practices, dental schools and other healthcare organizations, each of which consists of from one to 250 physicians or dentists. The Company believes that as healthcare providers are increasingly required to reduce costs while maintaining the quality of healthcare, the Company will be able to capitalize on its strategy of providing fully integrated information systems and superior client service. QSI is a California corporation formed in 1974 and was founded with an early focus on providing information systems and services primarily for dental group practices. QSI's initial "turnkey" systems were designed to improve productivity while reducing information processing costs and personnel requirements. In the mid-1980's, QSI capitalized on the opportunity presented by the increasing pressure of cost containment on 9 physicians and healthcare organizations and further expanded its information processing systems into the broader medical market. Today, QSI primarily develops and provides integrated character-based healthcare information systems utilizing a UNIX* operating system for both the medical and dental markets ("Legacy Product"). These expandable systems operate on a stand-alone basis or in a networked environment. Augmenting its medical practice management software system, QSI added Clinitec's electronic medical records software, NextGen** EMR, to its product line in 1995 and completed its acquisition of Clinitec in May 1996. NextGen EMR allows healthcare providers to create and maintain medical records using a series of user-definable clinical "templates." Data is generally captured using a light pen or a mouse, and entries are then turned into sentences and/or paragraphs to create documentation. NextGen EMR also supports the scanning and annotation of paper documents, photographs and X-rays, and contains many other advanced features. NextGen EMR is marketed both in conjunction with the Company's practice management software offerings as well as on a stand-alone basis where NextGen EMR may interface with other practice management systems. With the addition of NextGen EMR, the Company believes that it currently provides a comprehensive information management solution for the medical marketplace. During fiscal 1998, the Company released a new product, the Clinical Product Suite ("CPS"), a comprehensive dental solution designed specifically for the large dental group practice environment. CPS integrates the dental Legacy Product with a computer-based clinical information system that incorporates a wide range of clinical tools, including electronic charting of dental procedures, treatment plans and existing conditions; periodontal charting, via light-pen, voice-activation, or keyboard entry, for full periodontal examinations and PSR scoring; digital imaging of X-ray and intra-oral camera images; computer-based patient education modules; full access to patient information, treatment plans, and insurance plans; and document and image scanning for digital storage and linkage to the electronic patient record. CPS incorporates a Windows-based client-server technology consisting of one or more file servers together with any combination of one or more desktop, laptop, or pen-based PC workstations. The file server(s) used in connection with CPS utilize a Windows NT*** operating system. Based on the server configuration chosen, CPS is scalable from one to hundreds of workstations. Further augmenting its medical practice management system product line, the Company purchased MicroMed in May 1997. MicroMed develops and markets proprietary medical practice management systems. MicroMed's practice management system, NextGen EPM, has been developed with a client-server architecture; a GUI design utilizing either Windows 95***, Windows 98*** or Windows NT operating system platforms; and, a platform independent relational database that is ANSI SQL-compliant. NextGen EPM is designed to provide a flexible, enterprise-wide solution employing a master patient index. * UNIX is a registered trademark of AT&T Corporation. ** NextGen is a registered trademark of Clinitec International, Inc. *** Microsoft Windows, Windows NT, Windows 95 and Windows 98 are registered trademarks of Microsoft Corporation. 10 RISK FACTORS. COMPETITION. The market for healthcare information systems is intensely competitive and the Company faces significant competition from a number of different sources. The electronic medical records market, in particular, is subject to rapid changes in technology and the Company expects that competition in this portion of the market will increase as new competitors enter the marketplace. In addition, several of the Company's competitors have significantly greater name recognition as well as substantially greater financial, technical, product development and marketing resources than the Company. The industry is highly fragmented and includes numerous competitors, none of which the Company believes dominates the overall market for either group practice management or clinical systems. Furthermore, the Company also competes indirectly and to varying degrees with other major healthcare related companies, information management companies generally, and other software developers which may more directly enter the markets in which the Company competes. There can be no assurance that future competition or new product introductions will not have a material adverse effect on the Company's business, results of operations and financial condition. Competitive pressures and other factors, such as new product introductions by the Company or its competitors, may result in price or market share erosion that could have a material adverse effect on the Company's business, results of operations and financial condition. In addition, the Company believes that once a healthcare provider has chosen a particular healthcare information system vendor, the provider will, for a period of time, be more likely to rely on that vendor for its future information system requirements. Furthermore, if the healthcare industry continues to undergo further consolidation as it has recently experienced, each sale of the Company's systems will assume even greater importance to the Company's business, results of operations and financial condition. The Company's inability to make initial sales of its systems to either newly formed groups and/or healthcare providers that are replacing or substantially modifying their healthcare information systems could have a material adverse effect on the Company's business, results of operations and financial condition. If new systems sales do not materialize, maintenance service revenues can be expected to decrease over time due to the effect of failure to capture new maintenance revenues therefrom in combination with attrition of existing maintenance revenues associated with the Company's current clients whose systems become obsolete or are replaced by competitors' products. FLUCTUATION IN QUARTERLY OPERATING RESULTS. The Company's revenues and operating results have in the past fluctuated, and may in the future fluctuate, from quarter to quarter and period to period, as a result of a number of factors including, without limitation: the size and timing of orders from clients; the length of sales cycles and installation processes; the ability of the Company's clients to obtain financing for the purchase of the Company's products; changes in pricing policies or price reductions by the Company or its competitors; the timing of new product announcements and product introductions by the Company or 11 its competitors; the availability and cost of system components; the financial stability of major clients; market acceptance of new products, applications and product enhancements; the Company's ability to develop, introduce and market new products, applications and product enhancements and to control costs; the Company's success in expanding its sales and marketing programs; deferrals of client orders in anticipation of new products, applications or product enhancements; changes in Company strategy; personnel changes; and general economic factors. The Company's products are generally shipped as orders are received and accordingly, the Company has historically operated with minimal backlog. As a result, sales in any quarter are dependent on orders booked and shipped in that quarter and are not predictable with any degree of certainty. Furthermore, the Company's systems can be relatively large and expensive and individual systems sales can represent a significant portion of the Company's revenues for a quarter such that the loss of even one such sale can have a significant adverse impact on the Company's quarterly profitability. Clients often defer systems purchases until the Company's quarter end, so quarterly results generally cannot be predicted and frequently are not known until the quarter has concluded. The Company's initial contact with a potential customer depends in significant part on the customer's decision to replace, or substantially modify, its existing information system. How and when to implement, replace or substantially modify an information system are major decisions for healthcare providers. Accordingly, the sales cycle for the Company's systems can vary significantly and typically ranges from three to 12 months from initial contact to contract execution/shipment and the installation cycle is typically two to four months from contract execution/shipment to completion of installation. Because a significant percentage of the Company's expenses are relatively fixed, a variation in the timing of systems sales and installations can cause significant variations in operating results from quarter to quarter. As a result, the Company believes that interim period- to-period comparisons of its results of operations are not necessarily meaningful and should not be relied upon as indications of future performance. Further, the Company's historical operating results are not necessarily indicative of future performance for any particular period. Through March 31, 1998, the Company recognized revenue in accordance with the provisions of the American Institute of Certified Public Accountants ("AICPA") Statement of Position No. 91-1, "Software Revenue Recognition" ("SOP 91-1"). The AICPA adopted Statement of Position No. 97-2, "Software Revenue Recognition" ("SOP 97-2"), that supersedes SOP 91-1 and became effective for the Company on April 1, 1998. There can be no assurance that application and subsequent interpretations of this pronouncement by the Company, its independent auditors or the Securities and Exchange Commission will not further modify the Company's revenue recognition policies, or that such modifications would not have a material adverse effect on the operating results reported in any particular quarter. There can be no assurance that the Company will not be required to adopt changes in its licensing or services practices to conform to SOP 97-2, or that such changes, if adopted, would not result in delays or cancellations of potential sales of the Company's products. Due to all of the foregoing factors, it is possible that in some future quarter the Company's operating results may be below the expectations of public market analysts and investors. In such event, the price of the Company's Common Stock would likely be materially adversely affected. 12 ACQUISITIONS. During the past several years, the Company has made two significant acquisitions of relatively new companies, each of which has products utilizing newer technology than the Company's Legacy Product and each company having a limited sales history. Acquisitions involve a number of special risks, including possible adverse effects on the Company's operating results, diversion of management's attention, failure to retain key acquired personnel, amortization of acquired intangible assets, and risks associated with unanticipated events or liabilities, some or all of which could have a material adverse effect on the Company's business, results of operations and financial condition. Customer dissatisfaction or performance problems at a single acquired business can also have an adverse effect on the reputation of the Company. DEPENDENCE ON PRINCIPAL PRODUCT AND NEW PRODUCT DEVELOPMENT. The Company currently derives substantially all of its net revenues from sales of its healthcare information systems and related services. The Company believes that a primary factor in the market acceptance of its systems has been its ability to meet the needs of users of healthcare information systems. The Company's future financial performance will depend in large part on the Company's ability to continue to meet the increasingly sophisticated needs of its clients through the timely development, successful introduction and implementation of new and enhanced versions of its systems and other complementary products. The Company has historically expended a significant amount of its net revenues on product development and believes that significant continuing product development efforts will be required to sustain the Company's growth. There can be no assurance that the Company will be successful in its product development efforts, that the market will continue to accept the Company's existing or new products, or that products or product enhancements will be developed and implemented in a timely manner, meet the requirements of healthcare providers, or achieve market acceptance. If new products or product enhancements do not achieve market acceptance, the Company's business, results of operations and financial condition could be materially adversely affected. At certain times in the past, the Company has also experienced delays in purchases of its products by clients anticipating the launch of new products by the Company. There can be no assurance that material order deferrals in anticipation of new product introductions will not occur. TECHNOLOGICAL CHANGE. The software market generally is characterized by rapid technological change, changing customer needs, frequent new product introductions and evolving industry standards. The introduction of products incorporating new technologies and the emergence of new industry standards could render the Company's existing products obsolete and unmarketable. There can be no assurance that the Company will be successful in developing and marketing new products that respond to technological changes or evolving industry standards. New product development depends upon significant research and development expenditures which depend ultimately upon sales growth. Any material weakness in revenues or research funding could impair the Company's ability to respond to technological advances in the marketplace and remain competitive. If the Company is unable, for technological or 13 other reasons, to develop and introduce new products in a timely manner in response to changing market conditions or customer requirements, the Company's business, results of operations and financial condition will be materially adversely affected. In response to increasing market demand, the Company is currently developing new generations of certain of its software products designed for the client-server and Internet/intranet environments. There can be no assurance that the Company will successfully develop these new software products or that these products will operate successfully on the principal client-server operating systems, which include UNIX, Microsoft Windows, Windows NT, Windows 95 and Windows 98, or that any such development, even if successful, will be completed concurrently with or prior to introduction by competitors of products designed for the client-server and Internet/intranet environments. Any such failure or delay could adversely affect the Company's competitive position or could make the Company's current products obsolete. YEAR 2000 ISSUES. The Company is aware of issues associated with the programming code in existing computer systems with regard to the millennium change. In particular, software applications that use only two digits to identify a year in the date field may fail or create errors in the year 2000 ("Year 2000 Issues").Year 2000 Issues create risk for the Company from unforeseen problems in computer systems that the Company sells to customers on a nationwide basis which are used, among other things, to process their financial transactions and schedule patients ("Company Products"), as well as systems that the Company uses internally to provide certain services to its customers and to process its own financial transactions ("Internal Use Systems"). The potential costs and uncertainties associated with Year 2000 Issues depend upon a number of factors, including the Company's proprietary and third party developed software, hardware (hardware and third party developed software will hereinafter be referred to collectively as "Third Party Products") and the nature of the industry in which the Company operates. The nature of the Company's business and its relationships with its customers make it difficult to assess the magnitude of the Company's potential exposure as a result of Year 2000 Issues. Company Products and Third Party Products sold by the Company may fail to operate properly or as expected due to Year 2000 Issues. Such failures could result in system failures or miscalculations causing disruptions of customers' operations, including among other things, an inability to process transactions, send invoices, conduct communications, treat patients or engage in similar normal business activities. In addition, Company Products and Third Party Products are often used in conjunction with other vendors' products and services and the Company must rely on these other vendors to complete the material remediation efforts necessary with regards to Year 2000 Issues in connection with such products and services. Should such vendors be unable to complete such remediation efforts in a timely manner, the use of such products and services on the same system as Company Products and Third Party Products may result in system failures. As a result of one or more of the above potential system failures, certain of the Company's customers may assert breach of warranty or other claims against the Company relating to Year 2000 functionality. The assertion of such claims may have a material adverse impact upon the Company's business, results of operations and financial condition. Furthermore, the efforts and resources devoted to Year 14 2000 Issues of current and potential customers of the Company could result in the deferral, delay or cancellation by customers of current installations of and plans to purchase systems from the Company. Internal Use Systems, including both information systems and non-information systems, may not operate properly or as expected due to Year 2000 Issues. Year 2000 Issues could result in system failures or miscalculations causing disruption of the Company's operations, including among other things, an inability to process its own and certain of its customers' financial transactions, send invoices, conduct communications, or engage in similar normal business activities. The failure of one or more Internal Use Systems as a result of Year 2000 Issues may have a material adverse impact upon the Company's business, results of operations and financial condition. LITIGATION. On April 22, 1997, a purported class action was filed in California Superior Court on behalf of all persons who purchased the Company's Common Stock between June 26, 1995 and July 3, 1996. The complaint alleges that the Company and certain of its officers and directors, as well as other defendants not affiliated with the Company, violated sections of the California Corporations Code by issuing positive statements about the Company that allegedly were knowingly false, in part, in order to assist the Company and certain of its officers and directors in selling Common Stock at an inflated price in the Company's March 5, 1996 public offering and at other points during the period specified. On May 14, 1997, a second purported class action was filed in the same court essentially repeating the allegations of the April 22, 1997 suit. On July 1, 1997, a third purported class action was filed in the United States District Court repeating essentially the same factual allegations as the April 22, 1997 suit and purports to state claims under the Federal securities laws. The Company and its named officers and directors deny all allegations of wrongdoing made against them in these suits, consider the allegations groundless and without merit, and intend to vigorously defend against these actions. On March 23, 1999, a purported class action and derivative complaint was filed in the Superior Court of the State of California for the County of Orange, on behalf of all non-director shareholders, and derivatively on behalf of the Company, alleging that certain directors of the Company breached their fiduciary duties by allegedly entrenching themselves in their positions of control, failing to ensure that third-party offers involving the Company were fully and fairly considered, and/or failing to conduct a reasonable inquiry to assure the maximization of shareholder value. The complaint seeks declaratory and injunctive relief, an accounting of monetary damages allegedly suffered by plaintiff and the purported class, and attorneys' fees. The named directors deny all allegations of wrongdoing made against them in this suit, consider the allegations groundless and without merit, and intend to vigorously defend against the action. The pending Federal and state securities actions and the derivative action are in the early states of procedure. Consequently, at this time it is not reasonably possible to estimate the damage, or the range of damages, if any, that the Company might incur in connection with such actions. However, the uncertainty associated with substantial unresolved litigation may be expected to have an adverse impact on the Company's business. In particular, such litigation could impair the Company's relationships with existing customers and its ability to obtain new customers. Defending such 15 litigation will likely result in a diversion of management's time and attention away from business operations, which could have a material adverse effect on the Company's business, results of operations and financial condition. Such litigation may also have the effect of discouraging potential acquirors from bidding for the Company or reducing the consideration such acquirors would otherwise be willing to pay in connection with an acquisition. PROPRIETARY TECHNOLOGY. The Company is heavily dependent on the maintenance and protection of its intellectual property and relies largely on license agreements, confidentiality procedures, and employee nondisclosure agreements to protect its intellectual property. The Company's software is not patented and existing copyright laws offer only limited practical protection. There can be no assurance that the legal protections and precautions taken by the Company will be adequate to prevent misappropriation of the Company's technology or that competitors will not independently develop technologies equivalent or superior to the Company's. Further, the laws of some foreign countries do not protect the Company's proprietary rights to as great an extent as do the laws of the United States and are often not enforced as vigorously as those in the United States. The Company does not believe that its operations or products infringe on the intellectual property rights of others. However, there can be no assurance that others will not assert infringement or trade secret claims against the Company with respect to its current or future products or that any such assertion will not require the Company to enter into a license agreement or royalty arrangement with the party asserting the claim. As competing healthcare information systems increase in complexity and overall capabilities and the functionality of these systems further overlaps, providers of such systems may become increasingly subject to infringement claims. Responding to and defending any such claims may distract the attention of Company management and have a material adverse effect on the Company's business, results of operations and financial condition. In addition, claims may be brought against third parties from which the Company purchases software, and such claims could adversely affect the Company's ability to access third party software for its systems. ABILITY TO MANAGE GROWTH. The Company has experienced periods of growth and increased personnel, which has placed, and may continue to place, a significant strain on the Company's resources. The Company also anticipates expanding its overall software development, marketing, sales, client management and training capacity. In the event the Company is unable to identify, hire, train and retain qualified individuals in such capacities within a reasonable timeframe, such failure could have a material adverse effect on the Company. In addition, the Company's ability to manage future increases, if any, in the scope of its operations or personnel will depend on significant expansion of its research and development, marketing and sales, management, and administrative and financial capabilities. The failure of the Company's management to effectively manage expansion in its business could have a material adverse effect on the Company's business, results of operations and financial condition. 16 DEPENDENCE UPON KEY PERSONNEL. The Company's future performance also depends in significant part upon the continued service of its key technical and senior management personnel, many of whom have been with the Company for a significant period of time. The Company does not maintain key man life insurance on any of its employees. Because the Company has a relatively small number of employees when compared to other leading companies in the same industry, its dependence on maintaining its employees is particularly significant. The Company is also dependent on its ability to attract and retain high quality personnel, particularly highly skilled software engineers for applications development. The industry is characterized by a high level of employee mobility and aggressive recruiting of skilled personnel. There can be no assurance that the Company's current employees will continue to work for the Company. Loss of services of key employees could have a material adverse effect on the Company's business, results of operations and financial condition. Furthermore, the Company may need to grant additional stock options to key employees and provide other forms of incentive compensation to attract and retain such key personnel. PRODUCT LIABILITY. Certain of the Company's products provide applications that relate to patient clinical information. Any failure by the Company's products to provide accurate and timely information could result in claims against the Company. The Company maintains insurance to protect against claims associated with the use of its products, but there can be no assurance that its insurance coverage would adequately cover any claim asserted against the Company. A successful claim brought against the Company in excess of its insurance coverage could have a material adverse effect on the Company's business, results of operations and financial condition. Even unsuccessful claims could result in the Company's expenditure of funds in litigation and management time and resources. There can be no assurance that the Company will not be subject to product liability claims, that such claims will not result in liability in excess of its insurance coverage, that the Company's insurance will cover such claims or that appropriate insurance will continue to be available to the Company in the future at commercially reasonable rates. Such claims could have a material adverse affect on the Company's business, results of operations and financial condition. UNCERTAINTY IN HEALTHCARE INDUSTRY; GOVERNMENT REGULATION. The healthcare industry is subject to changing political, economic and regulatory influences that may affect the procurement processes and operation of healthcare facilities. During the past several years, the healthcare industry has been subject to an increase in governmental regulation of, among other things, reimbursement rates and certain capital expenditures. In the past, various legislators have announced that they intend to examine proposals to reform certain aspects of the U.S. healthcare system including proposals which may increase governmental involvement in healthcare, lower reimbursement rates and otherwise change the operating environment for the Company's clients. Healthcare providers may react to these proposals and the uncertainty surrounding such proposals by curtailing or deferring investments, including those for the Company's systems and related services. Cost-containment measures instituted by 17 healthcare providers as a result of regulatory reform or otherwise could result in greater selectivity in the allocation of capital funds. Such selectivity could have an adverse effect on the Company's ability to sell its systems and related services. The Company cannot predict what impact, if any, such proposals or healthcare reforms might have on its business, results of operations and financial condition. The Company's software may be subject to regulation by the U.S. Food and Drug Administration ("FDA") as a medical device. Such regulation could require the registration of the applicable manufacturing facility and software/hardware products, application of detailed record-keeping and manufacturing standards, and FDA approval or clearance prior to marketing. An approval or clearance could create delays in marketing, and the FDA could require supplemental filings or object to certain of these applications, the result of which could have a material adverse effect on the Company's business, results of operations and financial condition. 18 RESULTS OF OPERATIONS. The following table sets forth for the periods indicated, the percentage of net revenues represented by each item in the Company's consolidated statements of operations.
Three Months Nine Months Ended Ended December 31, December 31, ---------------- ---------------- 1999 1998 1999 1998 ------ ------ ------ ------ Net Revenues: Sales of computer systems, upgrades and supplies 50.4% 56.6% 55.0% 55.6% Maintenance and other services 49.6 43.4 45.0 44.4 ------ ------ ------ ------ 100.0 100.0 100.0 100.0 Cost of Products and Services 45.7 45.7 45.4 48.0 ------ ------ ------ ------ Gross Profit 54.3 54.3 54.6 52.0 Selling, General and Administrative Expenses 35.9 38.4 33.9 42.0 Research and Development Costs 10.9 9.5 10.2 11.0 ------ ------ ------ ------ Income (Loss) from Operations 7.5 6.4 10.5 (1.0) Investment Income 2.0 1.2 1.9 1.1 ------ ------ ------ ------ Income before Provision for Income Taxes 9.5 7.6 12.4 0.1 Provision for Income Taxes 4.1 3.4 5.4 0.8 ------ ------ ------ ------ Net Income (Loss) 5.4% 4.2% 7.0% (0.7)% ====== ====== ====== ======
19 FOR THE THREE-MONTH PERIODS ENDED DECEMBER 31, 1999 AND 1998. - ------------------------------------------------------------- The Company's net income for the three months ended December 31, 1999 was $475,000, or $0.08 per share on a basic and diluted basis, as compared to net income of $369,000, or $0.06 per share on a basic and diluted basis, for the three months ended December 31, 1998. Net Revenues. Net revenues were unchanged at $8.8 million for the three months ended December 31, 1999 and 1998. Sales of computer systems, upgrades and supplies decreased 11.3% to $4.4 million from $5.0 million while net revenues from maintenance and other services grew 14.3% to $4.4 million from $3.8 million during the comparable periods. The decrease in net revenues from sales of computer systems, upgrades and supplies was principally the result of a decrease in the sales of the Legacy Product. The increase in maintenance and other services net revenue resulted principally from an increase in revenues from the Company's increased client base from which to generate maintenance and other services revenue together with an increase in revenues generated from the Company's electronic data interchange services. Cost of Products and Services. Cost of products and services for the three months ended December 31, 1999 was unchanged at $4.0 million as compared to the three months ended December 31, 1998 and the cost of products and services as a percentage of net revenues was also unchanged at 45.7% for the respective periods. Selling, General and Administrative Expenses. Selling, general and administrative expenses for the three months ended December 31, 1999 decreased 6.6% to $3.2 million as compared to $3.4 million for the three months ended December 31, 1998. Selling, general and administrative expenses as a percentage of net revenues decreased to 35.9% from 38.4% as a result of the reduced expenses. The decrease in the amount of such expenses resulted primarily from the cost savings effected with the merger beginning in October 1998 of the NextGen EPM and NextGen EMR sales forces and the related marketing efforts. Research and Development Costs. Research and development costs for the three months ended December 31, 1999 increased 14.3% to $962,000 as compared to $842,000 for the three months ended December 31, 1998. Research and development costs as a percentage of net revenues increased to 10.9% as compared to 9.5% for the respective periods as a result of the effect of the increased research and development expenses. Investment Income. Investment income for the three months ended December 31, 1999 was $183,000 while investment income for the December 31, 1998 period was $109,000. The December 1998 quarter included recognition of a $39,000 unrealized loss in connection with an investment in a fund which traded in special situation securities. The investment was fully liquidated by March 31, 1999. There was no similar loss in the December 1999 quarter. The balance of the increase in the December 1999 quarter as compared to the December 1998 quarter was principally due to greater available cash balances for investment during the 1999 quarter. Provision for Income Taxes. The provision for income taxes for the three months ended December 31, 1999 was $365,000 as compared to $298,000 for the three months ended December 31, 1998. The provisions for income taxes for the three months ended December 31, 1999 and 1998 differ from 20 the combined statutory rates primarily due to the impact of non-deductible amortization of certain intangible assets acquired in the May 1996 Clinitec acquisition and the effect of varying state income tax rates. FOR THE NINE-MONTH PERIODS ENDED DECEMBER 31, 1999 AND 1998. - ------------------------------------------------------------ The Company's net income for the nine months ended December 31, 1999 was $2.0 million, or $0.31 per share on a basic and diluted basis, as compared to a net loss of ($171,000), or ($0.03) per share on a basic and diluted basis, for the nine months ended December 31, 1998. Net Revenues. Net revenues for the nine months ended December 31, 1999 increased 15.2% to $27.6 million from $24.0 million for the nine months ended December 31, 1998. Sales of computer systems, upgrades and supplies increased 13.8% to $15.2 million from $13.3 million, while net revenues from maintenance and other services grew 16.8% to $12.4 million from $10.6 million during the comparable periods. The increase in net revenues from sales of computer systems, upgrades and supplies was principally the result of increases in the sales of the CPS product and NextGen EPM and NextGen EMR systems offset in part by a decrease in sales of the Legacy Product. The increase in maintenance and other services net revenue resulted principally from an increase in revenues from the Company's increased client base from which to generate maintenance and other services revenue together with an increase in revenues generated from the Company's electronic data interchange services. Cost of Products and Services. Cost of products and services for the nine months ended December 31, 1999 increased 9.0% to $12.5 million from $11.5 million for the nine months ended December 31, 1998 while cost of products and services as a percentage of net revenues decreased to 45.4% from 48.0% during the comparable periods. The increase in the cost of products and services results from the impact of increased sales in the December 31, 1999 period together with a change in the relative mix of hardware content of such sales. The cost of products and services as a percentage of net revenues decreased as a result of the impact of increased sales in the December 31, 1999 period together with a change in the relative mix of hardware content of such sales. Selling, General and Administrative Expenses. Selling, general and administrative expenses for the nine months ended December 31, 1999 decreased 7.2% to $9.3 million as compared to $10.1 million for the nine months ended December 31, 1998. Selling, general and administrative expenses as a percentage of net revenues decreased to 33.9% from 42.0%. The decrease in the amount of such expenses resulted primarily from the cost savings effected with the merger beginning in October 1998 of the NextGen EPM and NextGen EMR sales forces and the related marketing efforts. The decrease of such expenses as a percentage of net revenues resulted from the increase in net revenues between the comparable periods together with the aforementioned cost savings. Research and Development Costs. Research and development costs for the nine months ended December 31, 1999 increased 7.2% to $2.8 million from $2.6 million for the nine months ended December 31, 1998. Research and development costs as a percentage of net revenues decreased to 10.2% as compared to 11.0% for the respective periods primarily as a result of the effect of the increase in net revenues for the December 1999 period. 21 Investment Income. Investment income for the nine months ended December 31, 1999 and 1998 was $531,000 and $260,000, respectively. The increase resulted principally from the recognition of a $242,000 unrealized loss during the 1998 period in connection with an investment in a fund which traded in special situation securities. The investment was fully liquidated by March 31, 1999. There was no similar unrealized loss in the 1999 period. Provision for Income Taxes. The provision for income taxes for the nine months ended December 31, 1999 and 1998 was $1.5 million and $202,000, respectively. The provision for income taxes for the nine months ended December 31, 1999 and 1998 differ from the combined statutory rates primarily due to the impact of non-deductible amortization of certain intangible assets acquired in the May 1996 Clinitec acquisition and the effect of varying state income tax rates. LIQUIDITY AND CAPITAL RESOURCES. Cash and cash equivalents increased $2.0 million for the nine months ended December 31, 1999 primarily as a result of cash provided by operating activities. Cash and cash equivalents decreased $2.6 million for the nine months ended December 31, 1998 primarily as a result of the payment of the final cash portion of the purchase price for the MicroMed business. Net cash provided by operating activities for the nine months ended December 31, 1999 was $3.3 million consisting primarily of the Company's $2.0 million in net income adjusted for the principal non-cash operating expenses of depreciation and amortization plus an increase in deferred service revenue offset in part by decreases in accounts payable and income tax related accounts. Net cash provided by operating activities for the nine months ended December 31, 1998 was $2.3 million consisting primarily of the Company's ($171,000) net loss adjusted for the principal non-cash operating expenses of depreciation and amortization plus an increase in deferred service revenue offset in part by an increase in income tax related accounts. Net cash used in investing activities for the nine months ended December 31, 1999 was $1.2 million consisting principally of additions to equipment and improvements and capitalized software. Net cash used in investing activities for the nine months ended December 31, 1998 was $4.7 million consisting principally of the $3.8 million cash portion of the final payment for the MicroMed business, plus additions to equipment and improvements and capitalized software offset in part by proceeds from the sale of certain short-term investments. Net cash used in financing activities for the nine months ended December 31, 1999 was $51,000 consisting of the purchase of 9,400 shares of the Company's Common Stock offset in part by proceeds from the exercise of stock options. Net cash used in financing activities for the nine months ended December 31, 1998 was $100,000 consisting of the purchase of 30,000 shares of the Company's Common Stock offset in part by proceeds from the exercise of stock options. In February 1997, the Company's Board of Directors authorized the repurchase on the open market of up to 10% of the Company's outstanding Common Stock at various times through February 1998, subject to compliance with applicable laws and regulations. On February 9, 1998, the Company's Board of Directors extended this authorization through February 9, 1999 and on February 9, 1999 further extended this authorization through February 22 28, 2000. The timing and amount of any repurchase is at the discretion of the Company's management. The Company's management could, in the exercise of its judgment, repurchase fewer shares than authorized. During the nine months ended December 31, 1999, the Company repurchased 9,400 shares at a cost of $57,000. Since the inception of the repurchase authorization through January 28, 2000, 109,900 shares have been repurchased at a cost of $630,000. At December 31, 1999, the Company had cash and cash equivalents of $16.2 million and short-term investments of $235,000. Except for the Company's intention to expend funds for the development of complementary products to its existing product line and alternative versions of certain of its products for the client-server environment to take advantage of more powerful technologies and to enable a more seamless integration of the Company's products, the Company has no other significant capital commitments and currently anticipates that additions to equipment and improvements for fiscal 2000 will be comparable to fiscal 1999. The Company believes that its cash and cash equivalents and short-term investments on hand at December 31, 1999, together with cash flows from operations, if any, will be sufficient to meet its working capital and capital expenditure requirements for the next year. 23 YEAR 2000 COMPLIANCE. INTRODUCTION. The Company is aware of issues associated with the programming code in existing computer systems with regard to the millennium change. In particular, software applications that use only two digits to identify a year in the date field may fail or create errors in the year 2000 ("Year 2000 Issues"). Year 2000 Issues create risk for the Company from unforeseen problems in computer systems that the Company sells to customers on a nationwide basis which are used, among other things, to process their financial transactions and schedule patients ("Company Products"), as well as systems that the Company uses internally to provide certain services to its customers and to process its own financial transactions ("Internal Use Systems"). The potential costs and uncertainties associated with Year 2000 Issues will depend upon a number of factors, including the Company's proprietary and third party developed software, hardware (hardware and third party developed software will hereinafter be referred to collectively as "Third Party Products") and the nature of the industry in which the Company operates. Company Products and Third Party Products sold by the Company may fail to operate properly or as expected due to Year 2000 Issues. Such failures could result in system failures or miscalculations causing disruptions of customers' operations, including among other things, an inability to process transactions, send invoices, conduct communications, schedule and treat patients or engage in similar normal business activities. Further, products and services used by the Company's customers, but not supplied by the Company, could fail to operate properly or as expected due to Year 2000 Issues. Customers' efforts to plan for such events could result in the deferral, delay or cancellation by customers of current installations of and plans to purchase systems from the Company. Similarly, Internal Use Systems, including both information systems and non-information systems, may not operate properly or as expected due to Year 2000 Issues. Year 2000 Issues could result in system failures or miscalculations causing disruption of the Company's operations, including among other things, an inability to process its own and certain of its customers financial transactions, send invoices, conduct communications, or engage in similar normal business activities. STATE OF READINESS. The Company has undertaken various initiatives intended to address Year 2000 Issues. The Company has identified individuals and/or working groups to (1) develop and implement the Company's definition of Year 2000 readiness; (2) assess Company Products, Third Party Products and Internal Use Systems for possible Year 2000 Issues; (3) monitor development, testing and remediation efforts with respect to Company Products, Third Party Products and Internal Use Systems; (4) monitor and coordinate the Company's deployment plans and results with respect to Year 2000 releases of Company Products, Third Party Products and Internal Use Systems; and, (5) develop contingency plans with respect to Company Products, Third Party Products and Internal Use Systems. Although the Company's efforts to address Year 2000 Issues do not fall precisely into sequential phases, generally these efforts are comprised of an assessment phase, a development phase (only with respect to Company Products and certain proprietary Internal Use Systems), a deployment or remediation phase, and a contingency planning phase. 24 Company Products. NextGen EPM, NextGen EMR and CPS are designed to be Year 2000 compliant and contain no known Year 2000 Issues when configured and used in accordance with the related documentation, and provided that the underlying operating system of the host machine and any other software used with or in the host machine are also Year 2000 compliant. However, there can be no assurance that such products do not contain undetected errors or defects associated with Year 2000 Issues. The Company's Legacy Product has required significant development and remediation efforts in connection with Year 2000 Issues with many of these efforts commencing in 1997. The Company completed its development efforts in connection with Year 2000 Issues associated with the Legacy product and certain associated ancillary products during calendar 1999. Also during calendar 1999, the Company completed deployment of Version 9 of its Legacy Product which version has been designed to be Year 2000 compliant. The Company continues to test and monitor performance of Version 9 and ancillary products in customer environments and expects to deliver and deploy maintenance releases in the ordinary course of business. Based on the Company's assessment to date, the Company believes continuing efforts will be required to assist customers in deploying and testing Version 9 in many of the customers' unique environments. The Company also expects an increase in service and support effort during the early months of the year 2000. Third Party Products Sold by the Company. The Company works closely with vendors of significant Third Party Products sold by the Company. In addition, Company Products have been tested with certain Third Party Products. Based upon its current assessments, the Company believes that it has received adequate assurances that significant Third Party Product vendors have successfully addressed their significant identified Year 2000 Issues on a timely basis. Due to uncertainties associated with Third Party Product vendors, the Company is unable to predict whether a material adverse effect on the Company's business, results of operations and financial condition may result from Year 2000 Issues related to Third Party Products despite the Company's current assessment to the contrary. Internal Use Systems. Based upon the Company's assessment efforts to date, the Company believes that its critical Internal Use Systems are Year 2000 compliant. Certain of the Internal Use Systems are proprietary and were developed by the Company. Company personnel have used similar techniques to identify Year 2000 Issues with its Company Products and proprietary Internal Use Systems. The critical proprietary Internal Use Systems have either been modified by Company personnel or replaced with third party developed systems which the Company believes will not fail as a result of Year 2000 Issues. The Company has communicated with developers and/or vendors of certain of its third party developed Internal Use Systems to determine the extent to which those products and services are Year 2000 compliant. Based upon its current assessments, the Company believes that it has received adequate assurances that critical third party developed Internal Use Systems are Year 2000 compliant. Contingency Plans. The Company has engaged in contingency planning to address company-wide personnel, resource, technical and communication matters in connection with foreseeable scenarios that may develop from Year 2000 Issues despite the Company's remediation efforts. The Company expects that its development, remediation, testing, deployment and contingency 25 planning efforts with respect to Company Products, Third Party Products and Internal Use Systems will continue beyond December 31, 1999. The Company's contingency planning includes possible (1) failure by the Company and its vendors to complete efforts to avoid or minimize the impact of Year 2000 Issues on a timely basis; (2) failure of customers to be ready for, or cooperate with, the deployment of Year 2000 compliant Company Products on a timely basis; and, (3) delay, deferral or cancellation by customers of current installations and prospective purchase decisions with respect to Company Products. A reasonably likely "worst case" scenario has not been identified, but it is anticipated that such scenario would include the failure of significant communications and computing infrastructures by the Company, its customers and its suppliers together with failures of infrastructures encompassing utilities, transportation, banking and government. COSTS. The total cost to address the Company's Year 2000 Issues were not material to the Company's financial condition. The Company does not separately track all of its internal personnel costs incurred in connection with identifying and resolving Year 2000 Issues. Excluding internal costs, total expenditures to address Year 2000 Issues were less than $100,000. All of these expenditures have been funded from operations. 26 PART II. OTHER INFORMATION. -------- ------------------ Item 6. Exhibits and Reports on Form 8-K. - ------- --------------------------------- (a) Exhibits: --------- The Exhibits listed on the accompanying Index to Exhibits on page 28 are filed as part of this report. (b) Reports on Form 8-K: -------------------- None. 27 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. QUALITY SYSTEMS, INC. Date: February 10, 2000 By /s/ Sheldon Razin ---------------------------------- Sheldon Razin President and Chairman of the Board of Directors; Principal Executive Officer Date: February 10, 2000 By /s/ Robert G. McGraw ---------------------------------- Robert G. McGraw Chief Financial Officer; Principal Accounting Officer
28 INDEX TO EXHIBITS Sequential Page Exhibit No. ------- ---------- 27.0 Financial Data Schedule, is filed herewith. 29 29 EXHIBIT 27.0 EX-27 2
5 9-MOS MAR-31-2000 DEC-31-1999 16,180,000 235,000 12,590,000 0 1,141,000 31,195,000 1,646,000 0 41,802,000 10,234,000 0 0 0 62,000 31,506,000 41,802,000 15,184,000 27,619,000 0 12,547,000 12,163,000 0 0 3,440,000 1,485,000 1,955,000 0 0 0 1,955,000 0.31 0.31
-----END PRIVACY-ENHANCED MESSAGE-----